JP Morgan Chase
RANI icon

JP Morgan Chase’s Rani Therapeutics RANI Stock Holding History

JP Morgan Chase’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.57K Sell
7,298
-521
-7% -$666 ﹤0.01% 6872
2025
Q4 		$10.6K Buy
7,819
+7,748
+10,913% +$11.7K ﹤0.01% 6661
2025
Q3 		$35 Hold
71
– – ﹤0.01% 7248
2025
Q2 		$36 Hold
71
– – ﹤0.01% 6919
2025
Q1 		$89 Hold
71
– – ﹤0.01% 6892
2024
Q4 		$97 Hold
71
– – ﹤0.01% 7011
2024
Q3 		$153 Hold
71
– – ﹤0.01% 6940
2024
Q2 		$270 Sell
71
-12,615
-99% -$65.4K ﹤0.01% 6746
2024
Q1 		$39.5K Buy
12,686
+8,988
+243% +$30.9K ﹤0.01% 6021
2023
Q4 		$12.3K Sell
3,698
-741
-17% -$1.71K ﹤0.01% 6357
2023
Q3 		$9.65K Sell
4,439
-2,086
-32% -$7.97K ﹤0.01% 6269
2023
Q2 		$26.9K Buy
6,525
+5,082
+352% +$23.6K ﹤0.01% 5853
2023
Q1 		$7K Buy
1,443
+654
+83% +$3.93K ﹤0.01% 6190
2022
Q4 		$5K Sell
789
-608
-44% -$4.43K ﹤0.01% 6170
2022
Q3 		$13K Buy
1,397
+209
+18% +$2.21K ﹤0.01% 5919
2022
Q2 		$12K Sell
1,188
-1,141
-49% -$13.1K ﹤0.01% 6004
2022
Q1 		$31K Sell
2,329
-1,857
-44% -$30.8K ﹤0.01% 5955
2021
Q4 		$68K Buy
+4,186
New +$95.1K ﹤0.01% 5833

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

JP Morgan Chase's RANI Position: Q1 2026 in Review

JP Morgan Chase reduced its Rani Therapeutics (RANI) stake by 6.7% in Q1 2026, selling an estimated $666 and leaving 7,298 shares worth $5.57K. The position accounts for ﹤0.01% of the portfolio, ranked #6872.

JP Morgan Chase first reported a position in RANI in Q4 2021 and has held it in 18 quarters since. The position peaked at $68K in Q4 2021. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • JP Morgan Chase held 7,298 shares of Rani Therapeutics worth $5.57K as of Q1 2026.
  • JP Morgan Chase sold 521 Rani Therapeutics shares in Q1 2026, an estimated $666.
  • Rani Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6872 holding.
  • JP Morgan Chase first reported a position in Rani Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • JP Morgan Chase's Rani Therapeutics position peaked at $68K in Q4 2021.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.